Dr. Pilar Eroles Asensio
Principal Investigator
Research Group on Breast Cancer Biology
Presentation
Dr. Eroles, a Miguel Servet researcher at the Carlos III National Health Institute, joined the Hospital Clínico de Valencia Research Foundation, currently the INCLIVA Research Institute, in 2004. In 2009, she was consolidated as a researcher within INCLIVA and she is currently Co-Principal Investigator of the Breast Cancer Biology Group of the institution.
Her line of research focuses on the study of the mechanisms of resistance to current treatments in breast cancer, evaluating the participation of the epithelial-mesenchymal transition, epigenetic modifications and the regulation of the tumor microenvironment. The objective of the group is to develop new therapeutic strategies to reverse resistance, based on the combination of biological agents and the development of new treatments such as nanoparticles.
She has participated in more than 30 funded projects, in 8 of them as principal investigator. She has publications in journals such as Cancer Cell, Blood, European Journal of Cancer and Oncotarget among others. She is an Associate Professor in the Department of Physiology of the Faculty of Medicine of the University of Valencia.
She has directed 8 completed doctoral theses and 3 currently in progress, as well as master’s degree projects and end-of-degree projects. She is a member of the INCLIVA Research Commission, a reviewer in several international scientific journals and an evaluator for the National Agency for Quality Assessment and Accreditation-ANECA.
Publications
Delivery of miR-200c-3p using tumor-targeted mesoporous silica nanoparticles for breast cancer therapy. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. ACS Applied Materials & Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. PMID: 37549382
Generation and characterization of trastuzumab/pertuzumab-resistant HER2-Positive breast cancer cell lines. Sanz-Alvarez M, Luque M, Morales-Gallego M, Cristóbal I, Ramírez-Merino N, Rangel Y, Izarzugaza Y, Eroles P, Albanell J, Madoz-Gúrpide J, Rojo F. International Journal of Molecular Sciences. 2023 Dec 22;25(1):207. doi: 10.3390/ijms25010207. PMID: 38203378
High VEGFR3 expression reduces doxorubicin efficacy in triple-negative breast cancer. Torres Ruiz S, Tormo E, Garrido Cano I, Lameirinhas A, Rojo F, Madoz Gurpide J, Burgues O, Hernando C, Bermejo B, Martinez MT, Lluch A, Cejalvo JM, Eroles P. International Journal of Molecular Sciences. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. PMID: 36835014
miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cabello P, Torres-Ruiz S, Adam-Artigues A, Fores-Martos J, Martinez M, Hernando C, Zazo S, Madoz-Gurpide J, Rovira A, Burgues O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo J, Eroles P. Cancers. 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. PMID: 37046799
CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer. Luque M, Cristobal I, Sanz-Alvarez M, Santos A, Zazo S, Eroles P, Arpi O, Rovira A, Albanell J, Madoz-Gurpide J, Garcia-Foncillas J, Rojo F. Journal of Clinical Medicine. 2022 Mar 14;11(6):1610. doi: 10.3390/jcm11061610. PMID: 35329936
MicroRNAs as a clue to overcome breast cancer treatment resistance. Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E, Cervera R, Eroles P. Cancer Metastasis Reviews. 2022 Mar;41(1):77-105. doi: 10.1007/s10555-021-09992-0. PMID: 34524579
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies. Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez J, Candela-Noguera V, Rojo F, Zazo S, Madoz-Gurpide J, Lluch A, Bermejo B, Sancenon F, Cejalvo J, Martinez-Manez R, Eroles P. Cancer Communications. 2022 Dec;42(12):1412-1416. doi: 10.1002/cac2.12352. PMID: 35997029
mTOR inhibition and trastuzumab-emtansine (T-DM1) in HER2-positive breast cancer. Casadevall D, Hernandez-Prat A, Garc A-Alonso S, Arpi-Llucia O, Menendez S, Qin M, Guardia C, Morancho B, Sanchez-Mart N F, Zazo S, Gavilan E, Sabbaghi M, Eroles P, Cejalvo J, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Molecular Cancer Research. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. PMID: 35348729
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. Adam-Artigues A, Garrido-Cano I, Simon S, Ortega B, Moragon S, Lameirinhas A, Constancio V, Salta S, Burgues O, Bermejo B, Henrique R, Lluch A, Jeronimo C, Eroles P, Cejalvo J. ESMO Open. 2021 Jan 18;6(1):100039. doi: 10.1016/j.esmoop.2020.100039. PMID: 33477007
Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients. Sanz-Alvarez M, Cristobal I, Luque M, Santos A, Zazo S, Madoz-Gurpide J, Carames C, Chiang C, Garcia-Foncillas J, Eroles P, Albanell J, Rojo F. Cancers. 2021 Mar 12;13(6):1246. doi: 10.3390/cancers13061246. PMID: 33809005
Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool. Garrido-Cano I, Pla L, Santiago-Felipe S, Simon S, Ortega B, Bermejo B, Lluch A, Cejalvo J, Eroles P, Martinez-Manez R. ACS Sensors. 2021 Mar 26;6(3):1022-1029. doi: 10.1021/acssensors.0c02222. PMID: 33599490
Oral Selective Estrogen Receptor Degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P, Garrido-Cano I, Adam-Artigues A, Lluch A, Bermejo B, Cejalvo J. International Journal of Molecular Sciences. 2021 Jul 22;22(15):7812. doi: 10.3390/ijms22157812. PMID: 34360578
Projects
Title: Predicción de enfermedad residual después de la terapia neoadyuvante en cáncer de mama HER2 positivo e identificación de estrategias para superar la resistencia
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2022 – 2024
Total budget: 123.420 €
Title: Caracterización y repercusión terapéutica de la ecología de cáncer de mama HER2 positivo
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Pilar Eroles Asensio
Duration: 2019 – 2021
Total budget: 112.530 €
Title: European Platform for Outcomes Research into Perioperative Interventions during Surgery for Cancer
Funding body: European Commission
Principal Investigator: Pilar Eroles Asensio
Duration: 2016 – 2020
Total budget:
+ Info
Doctoral candidate: Adam Artigues, Anna
Director(s): Lluch Hernández, Ana; Eroles Asensio, Pilar
Date of the defense: 12/04/2022
University: Universitat de València
Title: Role of miR-99a-5p in breast cancer: translating molecular findings into clinical tool
Doctoral candidate: Garrido Cano, Iris
Director(s): Eroles Asensio, Pilar; Martínez Máñez, Ramón
Date of the defense: 17/12/2021
University: Universitat Politècnica de València
Title: Involvement of EZH2-MYC loop and SALL4 in epithelial-mesenchymal transition (EMT) and trastuzumab resistance process in HER2+ breast cancer
Doctoral candidate: Pattanayak Pattanayak, Chaudhuri Birlipta
Director(s): Eroles Asensio, Pilar; Cejalvo Andújar, Juan Miguel
Date of the defense: 26/02/2021
University: Universitat de València
Title: Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: mirnas involved
Doctoral candidate: Cabello Navarro, Paula
Director(s): Erolés Asensio, Pilar; Lluch Hernández, Ana
Date of the defense: 28/09/2020
University: Universitat Politècnica de València